Recommended Articles
Fundraising

Pathos AI Raises $237 Million Series E Led by Bristol Myers Squibb at About $3 Billion Valuation

By Angeled · October 25, 2026 · Fundraising
Pathos AI Raises $237 Million Series E Led by Bristol Myers Squibb at About $3 Billion Valuation
Pathos AI Raises $237 Million Series E Led by Bristol Myers Squibb at About $3 Billion Valuation

Pathos AI has raised $237 million in a Series E funding round led by Bristol Myers Squibb, valuing the New York-based company at about $3 billion, with participation from existing investors. Announced on Friday, October 23, 2026, the financing arrived alongside a pair of strategic collaborations with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools and a patient dataset for research into Alzheimer's disease and other neurological disorders.

What Pathos AI does

Pathos AI is a clinical-stage technology company that builds an AI platform, called Pathos Foundry, for drug development. The platform's premise is that AI can improve the probability of success in drug development by generating and testing hypotheses about disease biology at scale and by informing the design of more targeted, adaptive clinical trials.

Pathos built that approach in cancer drug development, where Foundry guides decisions across the company's clinical-stage pipeline. Its current pipeline includes:

  • JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, which the company wants to move toward registrational studies
  • Pocenbrodib, being tested in metastatic castration-resistant prostate cancer and relapsed or refractory multiple myeloma
  • AZD4241, an ER PROTAC for ER-positive breast cancer, partnered with AstraZeneca
  • DO-2, a next-generation MET kinase inhibitor for MET-altered lung cancer

Proceeds from the financing will be used to further scale Foundry's capabilities and accelerate development of this AI-driven pipeline, including advancing JSKN016 and the AstraZeneca-partnered breast cancer programme. CEO Iker Huerga framed the platform as a system built to "improve the probability of success in drug development."

The Tempus neurology dataset

The second announcement may matter even more over time. Tempus will build a de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, tracking how their health changes over the years. Pathos will license that data under a five-year, $55 million agreement and run it through Foundry to generate and test hypotheses on disease biology and to design tighter trials.

Tempus will apply the infrastructure and expertise it has built in oncology to create the dataset. The companies gave no date for when it will be ready, and no date for when the first neurology trials will begin. Tempus disclosed that the Pathos neurology order form and a related side letter were reviewed and approved by a special committee of disinterested directors under its related-person transaction policy, citing overlapping executive leadership and equity ownership.

Separately, Tempus signed a multi-year oncology data and services agreement with Bristol Myers Squibb, with $137.5 million in aggregate fixed payments. Together, the two Tempus agreements provide for up to $192.5 million over approximately five years. These are commercial agreements, not part of Pathos's $237 million equity financing.

What Bristol Myers Squibb gets

Bristol Myers Squibb gains non-exclusive strategic access to Pathos Foundry across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programmes. "Neurological diseases demand more than any one company can bring on its own," Huerga said in the company's release. Tempus founder and CEO Eric Lefkofsky said: "Making meaningful progress against a disease as devastating as Alzheimer's requires unprecedented data scale and computing power."

Why a drugmaker leads the round

That a major drugmaker is leading the round says more than the amount. Pharmaceutical companies no longer just buy an AI tool; they take a stake in whoever builds it and reserve its use in their own therapeutic area. The structure — equity plus platform access plus exclusive neuroscience rights — gives Bristol Myers Squibb upside if Foundry works, and a privileged position in applying it to brain diseases.

Alzheimer's disease has been one of the hardest areas in medicine, with many costly trial failures. The bet is that AI insights, applied to a large longitudinal dataset, can help researchers understand disease progression and find the patients most likely to benefit from new treatments.

What it means for founders and investors

For founders in AI drug discovery, the Pathos round sets a template worth studying. The winning structure was not a software licence alone, but a bundle: equity investment from a strategic customer, platform access rights, and a data partnership that supplies the raw material the platform needs. Founders should ask whether their own go-to-market can offer a strategic partner something similarly exclusive — a therapeutic area, a dataset, a co-development right — rather than just a tool.

For investors, the $3 billion valuation on a pre-approval pipeline is a reminder of how much value the market assigns to AI drug-discovery platforms before clinical proof. Diligence should separate three things: the platform's demonstrated value in oncology, its unproven value in neurology, and the quality of the dataset that has not yet been built. Each carries different risk, and the financing's headline number blends them together.

Angeled.com connects founders with investors.

Sources: https://www.reuters.com/legal/litigation/pathos-ai-teams-up-with-bristol-myers-tempus-ai-advance-drug-development-2026-10-23/ , https://www.morningstar.com/news/dow-jones/202610235869/tempus-ai-expands-bristol-myers-partnership-with-multi-year-oncology-ai-data-deals , https://aistockwire.com/blog/pathos-ai-bristol-myers-bmy-237-million-tempus-tem-alzheimers-october-2026

Read Next